BA
ABCL icon

Bivin & Associates’s AbCellera Biologics ABCL Stock Holding History

Bivin & Associates’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50
Closed -$1K – 343
2021
Q4 		$1K Buy
+50
New +$759 ﹤0.01% 273

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
DB
DCVC Bio Palo Alto, California $313K AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return

Bivin & Associates's ABCL Position: Q1 2022 in Review

Bivin & Associates sold out of AbCellera Biologics (ABCL) in Q1 2022, closing a stake of 50 shares — an estimated $1K sold.

Bivin & Associates first reported a position in ABCL in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 130 funds tracked by Wall St. Rank hold ABCL as of Q1 2022.

  • Bivin & Associates reported no remaining AbCellera Biologics position as of Q1 2022 after selling out during the quarter.
  • Bivin & Associates sold 50 AbCellera Biologics shares in Q1 2022, an estimated $1K.
  • Bivin & Associates first reported a position in AbCellera Biologics in Q4 2021 and held it in 1 quarter.
  • Bivin & Associates's AbCellera Biologics position peaked at $1K in Q4 2021.
  • 130 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2022.

Based on Bivin & Associates's 13F filing for Q1 2022, filed 6 May 2022.